Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Interphex Showcase 2010.

Pharmaceutical Technology
Volume 34, Issue 4, pp. 128-135



Manufacturing capabilities
Lyne Laboratories offers its explosion-proof manufacturing capabilities for high-concentration, flammable pharmaceuticals. Lyne's state-of-the-art facility was designed specifically for formulations high in alcohol content and for solvent-based drug products. Batch sizes range from 1000 to 8000 L. Lyne is registered with the US Food and Drug Administration and licensed by the Drug Enforcement Administration. Lyne Laboratories, Brockton, MA http://www.lyne.com/ tel. 800.525.0450



Contract Services
Chemic Laboratories is a contract facility that follows good manufacturing and laboratory practices. The company offers extractables-leachables analysis, methods development and validations, bioanalytical services, organic synthesis and formulation development, and stability testing. The independent Chemic Consulting Consortium advises clients throughout their product-development cycles. Chemic Laboratories, Canton, MA http://www.chemiclabs.com/ tel. 781.821.5600



Contract services
Mikart has provided contract development, manufacturing, and packaging services to the pharmaceutical industry since 1975. The company's capabilities include formulation development; analytical services; solid- and liquid-dose manufacturing; packaging in bottles, blisters, and multilaminate pouches; project management; and regulatory services. Mikart, Atlanta, GA http://www.mikart.com/ tel. 888.4MIKART



Drug-delivery solutions
For more than 50 years, companies have looked to 3M Drug Delivery Systems for solutions to help their products meet the market's needs. 3M offers inhalation and transdermal drug-delivery systems and components, including dry-powder inhaler and microneedle technologies, plus state-of-the-art contract manufacturing services to help ensure technical success. 3M Drug Delivery Systems, St. Paul, MN http://www.3m.com/ tel. 800.643.8086


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here